S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:CAPR

Capricor Therapeutics - CAPR Stock Forecast, Price & News

$5.26
+0.16 (+3.14%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.00
$5.39
50-Day Range
$3.49
$5.28
52-Week Range
$2.56
$5.85
Volume
161,425 shs
Average Volume
228,337 shs
Market Capitalization
$127.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Capricor Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
185.2% Upside
$15.00 Price Target
Short Interest
Healthy
1.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of Capricor Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$185,292 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.17) to ($1.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

348th out of 1,122 stocks

Pharmaceutical Preparations Industry

163rd out of 551 stocks

CAPR stock logo

About Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Capricor Therapeutics to a "sell" rating in a research note on Monday, May 23rd.

Capricor Therapeutics Stock Up 4.3 %

NASDAQ:CAPR opened at $5.10 on Wednesday. The company has a market cap of $124.05 million, a P/E ratio of -4.90 and a beta of 5.00. Capricor Therapeutics has a fifty-two week low of $2.56 and a fifty-two week high of $5.85. The firm's 50 day moving average is $4.35 and its two-hundred day moving average is $4.02.

Capricor Therapeutics (NASDAQ:CAPR - Get Rating) last issued its earnings results on Wednesday, August 10th. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). During the same quarter last year, the firm earned ($0.21) EPS. Research analysts forecast that Capricor Therapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Activity

In other news, Director David B. Musket sold 28,215 shares of the firm's stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $3.77, for a total value of $106,370.55. Following the transaction, the director now owns 12,747 shares of the company's stock, valued at approximately $48,056.19. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director David B. Musket sold 28,215 shares of the firm's stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $3.77, for a total value of $106,370.55. Following the transaction, the director now owns 12,747 shares of the company's stock, valued at approximately $48,056.19. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David B. Musket sold 17,775 shares of Capricor Therapeutics stock in a transaction on Monday, June 27th. The stock was sold at an average price of $4.44, for a total transaction of $78,921.00. Following the sale, the director now directly owns 40,962 shares in the company, valued at approximately $181,871.28. The disclosure for this sale can be found here. Insiders own 9.00% of the company's stock.

Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CAPR Stock News Headlines

Capricor Therapeutics (CAPR) to Release Earnings on Wednesday
Finalist: Anthony J. Bergmann
See More Headlines
Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CAPR Company Calendar

Last Earnings
8/10/2022
Today
8/17/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CAPR
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+185.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-20,020,000.00
Pretax Margin
-11,122.06%

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$1.30 per share

Miscellaneous

Free Float
22,135,000
Market Cap
$127.94 million
Optionable
Not Optionable
Beta
5.00

Key Executives

  • Frank I. Litvack M.D. (Age 59)
    Independent Executive Chairman of the Board
  • Linda Marban Ph.D. (Age 51)
    President, Chief Executive Officer, Director
  • Anthony Bergmann (Age 32)
    Chief Financial Officer, Principal Accounting Officer
  • Karen G. Krasney J.D. (Age 62)
    Executive Vice President, General Counsel
  • Thomas Lyle Copmann Ph.D. (Age 61)
    Vice President - Regulatory Affairs and Drug Development
  • Houman Hemmati M.D.
    Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D.
    Vice President - Regenerative Therapies
  • Rachel Smith Ph.D. (Age 36)
    Vice President - Research & Development
  • Deborah Ascheim M.D.
    Chief Medical Officer
  • Joshua A. Kazam (Age 40)
    Director













CAPR Stock - Frequently Asked Questions

Should I buy or sell Capricor Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CAPR shares.
View CAPR analyst ratings
or view top-rated stocks.

What is Capricor Therapeutics' stock price forecast for 2022?

2 analysts have issued 12-month price objectives for Capricor Therapeutics' stock. Their CAPR share price forecasts range from $12.00 to $18.00. On average, they predict the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 185.2% from the stock's current price.
View analysts price targets for CAPR
or view top-rated stocks among Wall Street analysts.

How have CAPR shares performed in 2022?

Capricor Therapeutics' stock was trading at $2.93 at the beginning of 2022. Since then, CAPR shares have increased by 79.5% and is now trading at $5.26.
View the best growth stocks for 2022 here
.

When is Capricor Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CAPR earnings forecast
.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) issued its quarterly earnings results on Wednesday, August, 10th. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.04. During the same quarter in the previous year, the firm earned ($0.21) earnings per share.

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Who are Capricor Therapeutics' major shareholders?

Capricor Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Bailard Inc. (0.12%), UBS Group AG (0.12%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David B Musket and Xavier Avat.
View institutional ownership trends
.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $5.26.

How much money does Capricor Therapeutics make?

Capricor Therapeutics (NASDAQ:CAPR) has a market capitalization of $127.94 million and generates $250,000.00 in revenue each year. The biotechnology company earns $-20,020,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The official website for the company is www.capricor.com. The biotechnology company can be reached via phone at 310-358-3200, via email at kimberly@argotpartners.com, or via fax at 415-875-7075.

This page (NASDAQ:CAPR) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.